Form 4 for AKTX Akari Therapeutics Plc
Accepted 2024-06-04 00:00:00 ET · period of report 2024-05-31 · accession 0000950170-24-068771 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-06-04 | 2024-05-31 | AKTX | Patel Samir Rashmikant | Dir | A - Grant | $0.00 | +1.33B | 3.41B | +64% | $0 |
| DI | 2024-06-04 | 2024-05-31 | AKTX | Patel Samir Rashmikant | Dir | A - Grant | $0.00 | +1.33B | 1.33B | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value $0.0001 per share | 2024-05-31 | A | A | 1,326,258,000 | $0.00 | 3,411,495,500 | I PranaBio Investments LLC | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. (F2) On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant. |
| 2 | Derivative | Warrants (Right to Buy) | 2024-05-31 | A | A | 1,326,258,000 | $0.00 | 1,326,258,000 | I PranaBio Investments LLC | $0.00 · 2024-05-31 to 2027-05-31 | 1,326,258,000 Ordinary Shares, par value $0.0001 per share | (F2) On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant. (F3) The warrants have an exercise price of $0.000895 per Ordinary Share. |